HEG will conduct a Non-Deal Roadshow (NDR) and physical Institutional Investor Meetings in the Middle East on August 12 and 13, 2026. The sessions, scheduled from 11:00 AM to 6:00 PM, will take place in Dubai and Abu Dhabi. Senior management representatives will meet with leading fund houses and institutional investment firms to discuss the company’s business outlook, as part of an effort to enhance engagement with international capital markets.

The roadshow is being organized by 360 One Capital Market Research. The interactions will be conducted through physical group meetings. HEG has confirmed that its senior management and representatives participating in these sessions will not share, discuss, or disclose any Unpublished Price Sensitive Information (UPSI).

The disclosure was made pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company notified both BSE Limited and the National Stock Exchange of India Limited of the schedule on August 4, 2026.

Roadshow Schedule

The schedule is subject to change due to exigencies on the part of the investors or the company without prior notice. Viyek Chaudhary, Company Secretary of HEG Limited, signed the intimation. The corporate office is located in Noida, while the registered office is in Mandideep, Madhya Pradesh.

HEG Limited disclosed that Dr. Nand Gopal Khaitan, its Independent Director, purchased 5,000 equity shares in the company on August 3, 2026. The acquisition, executed through a market purchase on the National Stock Exchange (NSE), was valued at ₹33,31,810, translating to a price of ₹665.44 per share. This transaction brings Dr. Khaitan’s total holding to 5,000 shares, representing 0.0026% of the company’s total equity share capital.

The disclosure was made under Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. HEG Limited received the requisite intimation from Dr. Khaitan on August 4, 2026, and subsequently notified both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). The filing confirms that the director held nil securities prior to this acquisition.

Transaction Details

The specifics of the share purchase are outlined below:

Dr. Khaitan’s PAN is recorded as AFLPK3827K in the filing. The value of the transaction excludes taxes, brokerage, and other charges as per standard reporting norms under the SEBI PIT Regulations. There were no derivatives transactions reported alongside this equity purchase.

What the Numbers Show

The purchase by an independent director often signals confidence in the company’s future prospects or fair valuation at current market levels. With a holding of just 0.0026%, this remains a relatively small stake, but insider buying activity is closely monitored by investors as a potential indicator of management sentiment regarding the stock’s intrinsic value. The transaction was completed entirely on the open market, ensuring transparency in the execution.